Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Launched by MERZ PHARMACEUTICALS GMBH · Jun 18, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called NT 201, which is a type of botulinum toxin, to see if it can help reduce muscle stiffness (spasticity) in the legs caused by a stroke or traumatic brain injury. In this study, participants will receive either the NT 201 treatment or a placebo (which is a harmless substance with no medicine) to compare how effective the treatment is. The trial is open to people aged 18 to 85 who have specific types of leg muscle stiffness, and they must meet certain health criteria to join.

Participants can expect to receive a single injection of NT 201, and then they will be observed to see how well it works and whether it is safe. After the initial period, there may be additional treatment cycles to further assess safety and how well the treatment is tolerated. It's important to note that the study is currently looking for volunteers, and everyone will have an equal chance of receiving either the active treatment or the placebo during the first part of the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female or male subject ≥ 18 years and ≤ 85 years at screening
• • Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injury
• • Disabling ankle flexor spasticity presenting as pes equinus or pes equinovarus
• • Modified Ashworth Scale-Bohannon \[MAS\] score of 2 or 3 points in the ankle plantar flexor of the target lower limb (supine position, knee extended)
• • Minimum passive range of motion in ankle of the target lower limb (supine position, knee extended): 10°dorsiflexion and 20°plantarflexion
• • At least 4 months since last botulinum neurotoxin \[BoNT\] injection for treatment of spasticity or any other condition
• * For subjects receiving anticoagulation therapy, the investigator confirms and documents that the subject has an:
• • Activated partial thromboplastin time \[aPTT\] ≤ 80 seconds (subjects on dabigatran or other direct thrombin inhibitors) or
• • International normalized ratio \[INR\] value of ≤ 2.5 (subjects on coumarins or other anticoagulants monitored by INR)
• Exclusion Criteria:
• • Generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert Eaton syndrome, amyotrophic lateral sclerosis) or any other significant peripheral neuromuscular dysfunction which might interfere with the study
• • Bilateral lower limb paresis/paralysis/spasticity or tetraparesis/paralysis/spasticity
• • Body weight \< 50 kg
• • Severe atrophy of the target limb muscles
• • Previous, ongoing or planned treatments of spasticity with intrathecal baclofen
• • Previous, ongoing, or planned treatments of spasticity in the target lower limb with any of the following procedures: Surgical Intervention; Alcohol or phenol block; Muscle afferent block
• • Physiotherapy or use of orthoses or splints at the target limb initiated less than 4 weeks before screening or expected to change during the double blind phase of the study
• • Current or planned treatment with parenterally administered drugs that interfere with neuromuscular transmission (e.g. intrathecal baclofen, tubocurarine type muscle relaxants used in anesthesia), or local anesthetics in the treated region within 2 weeks prior to screening
• • Infection or inflammation at the injection sites
• • Subjects with presence or history of aspiration pneumonia, recurrent lower respiratory tract infections, or compromised respiratory function as per investigator's clinical judgment
• • Pregnancy (as verified by a positive pregnancy test) or breast feeding